Challenges and opportunities in the development and clinical implementation of artificial intelligence based synthetic computed tomography for magnetic resonance only radiotherapy.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
PMID:

Abstract

Synthetic computed tomography (sCT) generated from magnetic resonance imaging (MRI) can serve as a substitute for planning CT in radiation therapy (RT), thereby removing registration uncertainties associated with multi-modality imaging pairing, reducing costs and patient radiation exposure. CE/FDA-approved sCT solutions are nowadays available for pelvis, brain, and head and neck, while more complex deep learning (DL) algorithms are under investigation for other anatomic sites. The main challenge in achieving a widespread clinical implementation of sCT lies in the absence of consensus on sCT commissioning and quality assurance (QA), resulting in variation of sCT approaches across different hospitals. To address this issue, a group of experts gathered at the ESTRO Physics Workshop 2022 to discuss the integration of sCT solutions into clinics and report the process and its outcomes. This position paper focuses on aspects of sCT development and commissioning, outlining key elements crucial for the safe implementation of an MRI-only RT workflow.

Authors

  • Fernanda Villegas
    Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden; Radiotherapy Physics and Engineering, Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Solna, Sweden.
  • Riccardo Dal Bello
    Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
  • Emilie Alvarez-Andres
    OncoRay - National Center for Radiation Research in Oncology, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany; Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
  • Jennifer Dhont
    Maastro Clinic, Maastrict, the Netherlands.
  • Tomas Janssen
    Department of Radiation Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Lisa Milan
    Clinic of Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
  • Charlotte Robert
    U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France. Electronic address: ch.robert@gustaveroussy.fr.
  • Ghizela-Ana-Maria Salagean
    Faculty of Physics, Babes-Bolyai University, Cluj-Napoca, Romania; Department of Radiation Oncology, TopMed Medical Centre, Targu Mures, Romania.
  • Natalia Tejedor
    Department of Medical Physics and Radiation Protection, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Petra Trnková
    Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria.
  • Marco Fusella
    Department of Radiation Oncology, Abano Terme Hospital, Italy. Electronic address: mfusella@casacura.it.
  • Lorenzo Placidi
    Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Davide Cusumano
    Polo Scienze Oncologiche ed Ematologiche, Fondazione Policlinico Universitario Agostino Gemelli, Largo A. Gemelli, 8, 00168 Rome, Italy.